HOME >> MEDICINE >> NEWS
Surprising results for Ugandan HIV intervention trial

Results of a study in this week's issue of THE LANCET show how interventions to promote safer sex and the control of sexually transmitted diseases did not reduce the incidence of HIV infection in an area of rural Uganda.

Treatment of sexually transmitted infections (STIs) and behavioural interventions are the main methods to prevent HIV in developing countries. Anatoli Kamali from the Medical Research Council Programme on AIDS in Uganda and colleagues assessed the effect of behaviour change and STI management on the incidence of HIV-1 and other STIs in Uganda.

All adults living in 18 communities in rural Uganda were randomly allocated into three groups: the first group received behavioural interventions alone (promotion of safer sex behaviour); the second group received both behavioural and STI interventions; the third was a control group where individuals received routine government health services and community development activities.

Follow-up took place after three and a half to four years. Only condom use with last casual partner increased significantly more in the two intervention groups compared with the control group. Despite significant reductions in acute syphilis, gonorrhoea, and unprotected casual sex in the combined intervention group, there was no effect on HIV incidence attributable to either intervention. The investigators comment that more effective STI and behavioural interventions need to be developed for HIV control in mature epidemics in countries like Uganda.

Judith Stephenson and Frances Cowan from the Royal Free and University College Medical School, London, UK, observe in an accompanying Commentary (p 633) that the timing of the study could partly explain the surprising results; the fact that the overall HIV incidence is falling in Uganda suggests that the study could have been underpowered to detect substantial differences in HIV incidence between the intervention and control groups. They conclude: "What does this tria
'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
20-Feb-2003


Page: 1 2

Related medicine news :

1. Surprising findings on Medicaid kids and the ER
2. New studies show mixed results on epilepsy drugs and birth defects
3. Study of obese diabetics explains why low-carb diets produce fast results
4. Sharing clinical trial results with participants may be beneficial
5. Emergency clopidogrel could save thousands of lives46,000-patient heart attack trial results
6. Similar results found in both older and younger patients undergoing weight-loss surgery
7. OHSU researcher says FDA could broaden access to results of clinical drug trials
8. Kinder, gentler procedure gives superior results for stem cell transplants
9. Good results with only one egg in in-vitro fertilization
10. Holiday feasting could sabotage liposuction results
11. Early results shed light on lung cancer screening advance

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Surprising results for Ugandan HIV intervention trial

(Date:4/23/2014)... "simple and accessible detection methods that can rapidly ... of a single cell inside that population has ... Chang Lu. , In the Royal Society of ... announced that he and his coworkers have developed ... of a protein ( Chem. Sci. , 2014, ...
(Date:4/23/2014)... are often displayed in the popular Swedish children,s ... of high-sugar foods. A new study from the ... in children,s TV programmes as well as the ... and weight status. , Steingerdur Olafsdottir,s doctoral thesis ... popular Swedish children,s TV show Bolibompa. Healthy foods ...
(Date:4/23/2014)... led by a researcher from the Cancer Science Institute ... Singapore has identified the cancer specific stem cell which ... of developing new drugs for the treatment of this ... group, led by Dr Chan Shing Leng, Research Assistant ... that a cancer-specific variant of a cell surface protein, ...
(Date:4/23/2014)... in the journal Oncotarget , explored tumour ... or their own DNA signatures within the same ... design effective, targeted treatment strategies. , Firstly they ... and either the KRAS or BRAF mutation. Secondly, ... EGFR gene mutation have that specific mutation present ...
(Date:4/23/2014)... Alzheimer,s disease has been a rapidly evolving pursuit ... latest crook in the research road, scientists have ... proteins associated with the disease. The report, which ... , could have important implications for developing novel ... colleagues explain that for years, research has suggested ...
Breaking Medicine News(10 mins):Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2Health News:High-calorie and low-nutrient foods in kids' TV 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 2Health News:Scientists identify cancer specific cell for potential treatment of gastric cancer 3Health News:Non-uniform genetic mutations identified in lung cancers could lead to targeted treatment 2
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com announces ... available in its catalogue: ... Forecast and Market Analysis to 2022 ... Atopic Dermatitis - India Drug Forecast and ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a ... needs of severely obese patients, today announced initial ... a selective inhibitor of methionine aminopeptidase 2 (MetAP2), ... form of genetic obesity.  These results showed improvements ...
(Date:1/14/2014)... InformEx, North America,s leading business partnering ... the 30 th edition of its annual conference at ... January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... and specialty chemical companies will take part in the conference, ...
Breaking Medicine Technology:PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 2PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 3PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 4PharmaPoint: Atopic Dermatitis - India Drug Forecast and Market Analysis to 2022 5Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
Cached News: